Nur Khamidah, Evy Ervianti

Abstract views = 1341 times | downloads = 2918 times


Onychomycosis is a fungal infection of the nail unit including the nail matrix, the nail bed and the nail plate by both dermatophyte and non-dermatophyte agents. It is disturbs not only cosmetic disfigurement, but also it may have an impact on patients’ emotional, social and occupational functioning, finally affecting the overall quality of life. The incidence rate tends to increase, management of onychomycosis is still challenging. Important problems regarding antifungal monotherapy have experienced many failures and recurrences. In general, pharmacological approaches for onychomycosis can be topical or oral antifungal. Antifungal monotherapies often lead to failure treatment, also high incidence of recurrence. One strategy for this problem is a combination antifungal therapy. In vitro studies show the synergistic effect of using combination two antifungals (both oral antifungal or combination topical and oral antifungal), hence it is mycologically or clinically expected to increase the success rate of onychomycosis therapy. This review tries to evaluate the previous study exploring the effectiveness of antifungal combination therapies on onychomycosis. Two oral antifungals usually used are terbinafine as fungicidal agent and itraconazole as fungistatic agent. There is combination between topical and oral antifungal such as itraconazole or terbinafine with amorolfine or ciclopirox, also other combination like griseofulvin and amorolfone or tioconazole. All the combination therapies show better result than monotherapy alone, but it is still difficult to conclude whether antifungal combinations in onychomycosis will increase effectiveness due to variations in therapeutic duration, result definition, and statistical evaluation on existing studies. Further research is required with longer duration of observation, uniform patient criteria and definition of success, random control and blinding to minimize bias.


antifungal; combination; therapy; onychomycosis; effectiveness

Full Text:



Vora D, Bharti B, Solanki P, Kothari A, Meher K. A study to compare efficacy of various oral antifungals (Fluconazole, Terbinafine, Itraconazole) in treatment of Onychomycosis. J Res Med Dent Sci. 2014;2(4):49.

Piraccini B, Alessandrini A. Onychomycosis: A Review. J Fungi. 2015 Mar 27;1(3):30–43.

Evans EG. The rationale for combination therapy. Br J Dermatol. 2001 Oct;145 Suppl:9–13.

Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003 Sep;149 Suppl:15–8.

Gupta AK, Daigle D, Foley KA. Network Meta-Analysis of Onychomycosis Treatments. Ski appendage Disord. 2015 Sep;1(2):74–81.

Tabara K, Szewczyk AE, Bienias W, Wojciechowska A, Pastuszka M, Oszukowska M, et al. Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis. Adv Dermatology Allergol. 2015;1:40–5.

K B, S S, W I, LM R, S W, E E. Dermatomikosis Superfisialis Pedoman Dokter dan Mahasiswa Kedokteran. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2013. 86-89 p.

Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014 Nov;171(5):937–58.

Córdoba-Fernández A, Távara-Vidalón P, Mandredi-Márquez MJ. Therapeutic approach for toenail onychomycosis: Literature review and cost-effectiveness analysis. foot Ankle Online J 7. 2014;2(3):3–10.

Lipner SR, Scher RK. Prognostic Factors in Onychomycosis Treatment. Infect Dis Ther. 2015;3(1):1–6.

Wolff K, La G, Si K. Fitzpatrick ’ s Dermatology in Gener- al Medicine . Seventh Edition . Two. 2009;17(2):149–50.

Ayanlowo O, Oladele RO. Onychomycosis: updates and management challenges. A review. Niger Postgrad Med J. 2014 Jun;21(2):185–91.

Vlahovic TC. Onychomycosis: Evaluation, Treatment Options, Managing Recurrence, and Patient Outcomes. Clin Podiatr Med Surg. 2016 Jul;33(3):305–18.

Gupta AK, Daigle D, Foley KA. Topical therapy for toenail onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014 Dec;15(6):489–502.

Sigurgeirsson B, Olafsson JH, Steinsson JT, Kerrouche N, Sidou F. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol. 2010 Aug;24(8):910–5.

Shenoy MM, Shenoy MS. Fungal nail disease (Onychomycosis); Challenges and solutions. Arch Med Heal Sci. 2014;2(1):48.

Nenoff P, Krüger C, Paasch U, Ginter-Hanselmayer G. Mycology - an update Part 3: Dermatomycoses: topical and systemic therapy. J Dtsch Dermatol Ges. 2015 May;13(5):387–410; quiz 411.

Gupta AK, Paquet M. Improved efficacy in onychomycosis therapy. Clin Dermatol. 31(5):555–63.

Gupta AK, Cooper EA, Paquet M. Recurrences of dermatophyte toenail onychomycosis during long-term follow-up after successful treatments with mono- and combined therapy of terbinafine and itraconazole. J Cutan Med Surg. 17(3):201–6.

Lecha M, Alsina M, Torres Rodríguez JM, de Erenchun FR, Mirada A, Rossi AB. An open-label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res. 2002 Jun;63(6):366–79.

Rigopoulos D, Katoulis AC, Ioannides D, Georgala S, Kalogeromitros D, Bolbasis I, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol. 2003 Jul;149(1):151–6.

Baran R, Feuilhade M, Combernale P, Datry A, Goettmann S, Pietrini P, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br J Dermatol. 2000 Jun;142(6):1177–83.

Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat. 2005;16(5–6):327–30.

Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 4(4):481–5.

Jaiswal A, Sharma RP, Garg AP. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol. 73(6):393–6.

Baran R, Sigurgeirsson B, de Berker D, Kaufmann R, Lecha M, Faergemann J, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix invol. Br J Dermatol. 2007 Jul;157(1):149–57.

Ghannoum MA, Long L, Isham N, Bulgheroni A, Setaro M, Caserini M, et al. Ability of hydroxypropyl chitosan nail lacquer to protect against dermatophyte nail infection. Antimicrob Agents Chemother. 2015 Apr;59(4):1844–8.

Ghannoum M, Isham N, Catalano V. A second look at efficacy criteria for onychomycosis: clinical and mycological cure. Br J Dermatol. 2014 Jan;170(1):182–7.

Scher RK, Tavakkol A, Sigurgeirsson B, Hay RJ, Joseph WS, Tosti A, et al. Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol. 2007 Jun;56(6):939–44.

Ghannoum M, Sevin K, Sarkany M. Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay. Dermatol Ther (Heidelb). 2016 Mar;6(1):69–75.


  • There are currently no refbacks.

Copyright (c) 2018 Indonesian Journal of Tropical and Infectious Disease

View My Stats

IJTID Indexed by : 


IJTID (pISSN 2085-1103eISSN 2356-0991is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Lembaga Penyakit Tropis (Institute of Tropical Disease)

Universitas Airlangga

Kampus C Mulyorejo

Surabaya 60115